Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of ...

Merck, known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYFORM -007 trial evaluating the investigational fixed-dose combination of favezelimab, Merck’ s ...

Merck, known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...

Merck MRK decided to discontinue two clinical development programs, namely KeyVibe and KEYFORM, which are evaluating its ...

Merck: Favezelimab/Keytruda Combo Study Misses Goal in Colorectal Cancer Provided by Dow Jones Sep 25, 2024, 11:20:00 AM. By Colin Kellaher .

Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of ...

On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for ...

RAHWAY, N.J., September 25, 2024--Update on KEYFORM-007 Trial Evaluating Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1+ MSS mCRC ...

On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for ...

Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve overall survival compared to standard treatments, though safety remained ...